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low-density lipoprotein (LDL) cholesterol and subsequently lead
to cardiovascular events. OBJECTIVE: To examine the associa-
tion of variable patient compliance with statins to the control of
serum LDL. METHODS: A 6-month prospective observational
cohort study was conducted at the outpatient clinics of a public
teaching hospital in Hong Kong. Patients with a 10-year risk for
CHD > 20% or CHD risk equivalents who had been initiated
on statin monotherapy for < 12 months were recruited. The
statin prescription was dispensed to study patients in a bottle
with the Medication Event Monitoring System (MEMS) to
record the date and time the bottle cap was removed and
replaced. Lipid proﬁles were obtained at baseline and two
follow-up visits at month 3 and month 6. RESULTS: A total of
82 patients were recruited and 60.1% were male (mean age = 60
± 12.3 years). Duration of statin treatment prior to study was
6.9 ± 3.2 months. Baseline LDL prior to statin therapy was 3.8
± 0.71mmol/L. Interim ﬁndings showed that LDL was reduced
by 39 ± 14.2% with 84 ± 20% compliance measured as days
with correct dosing at month 3. Signiﬁcant linear relationship
was shown between LDL reduction and days with correct dosing
(R = 0.4848, p = 0.0015), dose count (R = 0.4535, p = 0.002)
but not timing of dose (R = 0.4959, p = 0.09). A 30% reduction
in serum LDL was corresponded to 80% compliance (days with
correct dosing). CONCLUSION: LDL reduction was correlated
with compliance to statin, and 30% LDL reduction appeared to
be achieved at 80% compliance with the prescribed statin
therapy.
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OBJECTIVE: To describe the patterns and predictors of adher-
ence with concomitant antihypertensive (AH) and lipid-lowering
(LL) therapies. METHODS: This retrospective cohort study
evaluated 8406 enrollees in a US managed care plan. Participants
initiated both AH and LL therapies within a 90-day period.
Adherence with AH and LL medications was measured at 3-
month intervals from the start of concomitant therapy for up to
36 months (mean follow-up 12.9 months). Patients were con-
sidered “adherent” with AH and LL therapies if they had ﬁlled
sufﬁcient prescriptions to cover at least 80% of days with both
classes of medications. A multivariate regression model evalu-
ated potential predictors of adherence with concomitant therapy,
including patient demographics, clinical characteristics, and
health service use patterns at baseline. RESULTS: Six months
after treatment initiation, only 36% of patients were adherent
with both AH and LL therapies, 35% did not adhere to either
regimen, and an additional 29% of patients were adherent with
either AH or LL therapy, but not both. These proportions
remained relatively steady over time. In the multivariate model,
age, gender, time since treatment began, and a history of coro-
nary heart disease or congestive heart failure were independently
associated with the likelihood of being adherent. The number of
other medications a patient was taking in the pretreatment year
was strongly and inversely associated with adherence to con-
comitant therapy. In addition, patients were more likely to be
adherent with concomitant therapy if they initiated AH and LL
therapy on or about the same date (within 0–30 days of each
other). CONCLUSIONS: Adherence with concomitant AH and
LL therapy is poor, with only 1 in 3 patients adherent to both
medications at 6 months. Initiating AH and LL therapy together
and keeping the number of other medications to a minimum may
improve adherence with concomitant therapy.
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OBJECTIVES: One study documented that physicians tend to
avoid giving prophylaxis to orthopedic patients taking aspirin
due to the concern of increased bleeding, though there is no clear
evidence from the literature. The aim of this study is to deter-
mine whether giving LMWH to patients taking aspirin increases
the hemorrhage risk compared with having only aspirin or
LMWH. This project will also demonstrate the use of the regres-
sion method in outcome research with a large administrative
database. METHODS: Diagnoses and procedures coded in ICD-
9-CM from 15 hospitals across the U.S. that include a mix of
hospital types and geographical locations. In the database, there
were 6847 orthopedic surgery patients who are given LMWH or
aspirin or both: 3680 undergoing hip replacement and 3167
undergoing knee replacement surgery. Logistic regression was
done to assess the bleeding risk. Independent variables included
are anticoagulants taking, procedure (hip/knee), length of stay
(LOS), age, gender, and comorbidities. SAS® for Windows® was
used in the statistical analysis. RESULTS: Combination use of
aspirin and LMWH results higher hemorrhage risk than aspirin
only (p < 0.0001). Combination use of aspirin and LMWH does
not result in different hemorrhage risk than LMWH only 
(p = 0.53). Hip replacement patients have a lower risk than knee
replacement patients. Patients with longer LOS and older
patients have a higher bleeding risk. There was no difference in
bleeding risk by sex. Comorbidities associated with a higher
bleeding risk included cardiovascular diseases, rheumatologic
disease, peptic ulcer, renal disease, malignancy, neurological dis-
orders, drug abuse, and depression. CONCLUSIONS: Based on
our ﬁndings, giving LMWHs to patients taking aspirin results in
more bleeding compared to aspirin alone. However, aspirin does
not inﬂuence the risk of bleeding due to LMWH signiﬁcantly so
patients taking aspirin can receive LMWH. Factors, such as 
age and comorbidities, should be considered before giving
thromboprophylaxis.
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OBJECTIVE: Cholesterol lowering has been shown to reduce
cardiovascular morbi-mortality. National and international (e.g,
US NCEP) guidelines have deﬁned LDL-C treatment initiation
levels (TIL) and goals for patients with different levels of coro-
nary heart disease (CHD) risk according to the number of CHD
risk factors (CRF) associated to dyslipidemia or to prior CHD.
The objective of this study was to measure the proportions 
of patients above AFSSAPS* TIL [1 CRF > 220mg/dl; 2 CRF >
190mg/dl; 3 CRFs > 160mg/dl; > 3 CRFs and prior CHD >
130mg/dl] and NCEP goal in patients with different CHD risk
level and treated with lipid lowering agents (LLA). METHOD:
